ET Saturday, June 6 DALLAS, JUNE 6, 2026 Among adults with both obesity and an autoimmune disease, those taking a glucagon-like peptide-receptor 1 agonist (GLP-1RA) medication had lower rates of emergency department visits and were less likely to experience serious cardiac events, such as stroke, pulmonary embolism or death when compared to similar adults who were not taking these medications, according to new research published today in the Journal of the American Heart Association , an open-access, peer-reviewed journal of the American Heart Association
Berk M, Dean O, Cotton SM, Gama CS, Kapczinski F, Fernandes BS, Kohlmann K, Jeavons S, Hewitt K, Allwang C, Cobb H, Bush AI, Schapkaitz I, Dodd S, Malhi GS
Grey market grows for cheap weight-loss drugs imported from China Some users try small doses of substances not yet approved by FDA Drugmakers call trend dangerous and illicit Online community says its filling gaps in broken system SAN FRANCISCO, June 29 In what she calls the wild west of obesity medicines, Missouri-based Amy Spencer is a pioneer
However, using a degraded peptide means dosing becomes unpredictable, since you cannot know how much active compound remains
It made me realize how rare that kind of transparency is
